By Vishwadha Chander
Jul 30 (.) – Antibody drug used against coronavirus in Cuba decreased the risk of admission to intensive care and death among nursing home residents with moderate COVID-19, according to a small study conducted on the island .
Researchers who included Cuba’s Center for Molecular Immunology, which developed itolizumab, said that the timely use of the drug in combination with standard therapy helped reduce inflammation and prevented COVID-19 from worsening.
The 19 hospitalized patients from a single nursing home had tested positive for the virus in April.
All were over 64 years old and suffered from chronic problems such as hypertension, dementia, heart disease, diabetes and lung diseases. Your age and health problems are considered risk factors for severe COVID-19.
Patients received one or two intravenous doses of itolizumab together with the standard treatments used in Cuba, such as antiviral drugs, antibiotics, chloroquine, interferon, and anticoagulants.
Only two patients required oxygen therapy after the first dose, and all but one were discharged from the hospital in 14 days. (Edited in Spanish by Javier Leira)